NDAINJECTIONINJECTABLE
Approved
Dec 1951
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Wyamine Sulfate (mephentermine sulfate) is an injectable sympathomimetic amine approved in 1951 for acute hypotensive episodes. It works as an adrenergic agonist to elevate blood pressure by stimulating alpha and beta adrenergic receptors. The drug is administered intravenously or intramuscularly in acute clinical settings.
LOE Approaching
This legacy injectable faces LOE with minimal commercial infrastructure; career opportunities are declining as modern vasopressors displace this 70+ year-old agent.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Wyamine Sulfate offers very limited career upside; this legacy injectable with zero linked job postings faces LOE and competes in a commoditized vasopressor market. Professionals should expect small teams, minimal growth trajectory, and limited development opportunities compared to marketed growth-stage products.
Specialty Sales RepresentativeHospital Account Manager
Worked on WYAMINE SULFATE at Baxter? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.